Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 IQVIA, Argenx Partner to Accelerate Clinical Development of VYVGART | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

IQVIA, Argenx Partner to Accelerate Clinical Development of VYVGART

Collaboration to support clinical development, regulatory, commercial and real-world evidence to accelerate the development of new indications for VYVGART.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

IQVIA entered an agreement with Argenx SE for the development of new indications for VYVGART (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult patients who have a specific antibody receptor. Terms of the agreement were not disclosed.
 
The collaboration will support clinical development, regulatory, commercial and real-world evidence strategy to accelerate the development of new indications for VYVGART.
 
IQVIA will leverage its scientific expertise, technology and analytics to support Argenx in accelerating the clinical development of VYVGART.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics